Kimberly-Clark closes its acquisition of Tylenol maker Kenvue. What to expect next — Live Feedhttps://www.live-feeds.com/feed/kimberly-clark-closes-its-acquisition-of-tylenol-maker-kenvue-what-to-expect-nextContinuously updated, source-cited coverage. Kimberly-Clark Completes Acquisition of Kenvuehttps://www.live-feeds.com/feed/kimberly-clark-closes-its-acquisition-of-tylenol-maker-kenvue-what-to-expect-nexthttps://www.live-feeds.com/feed/kimberly-clark-closes-its-acquisition-of-tylenol-maker-kenvue-what-to-expect-next#u179072Thu, 05 Nov 2026 23:21:17 +0000Kimberly-Clark closed its acquisition of Kenvue on November 2, absorbing the maker of Tylenol and Listerine to form a global consumer health and wellness business. The deal, valued between $40 billion and $49 billion, results in Kenvue stock being delisted from the NYSE. Kimberly-Clark has integrated former Kenvue executives into its leadership and launched a $3.1 billion integration program scheduled to run through 2029. The company aims to use the merger to improve overall growth and earnings.Why it mattersThis merger combines Kimberly-Clark's existing portfolio with Kenvue's healt